AKT1 and prostate carcinoma: However, in numerous cancer types including prostate cancer, mTOR complex 1 inhibition by rapamycin had a limited therapeutic efficacy in part due to the loss of negative feedback loops leading to the activation of AKT by TORC2 [43].